Zkušenosti s léčbou ruxolitinibem u pacientu s myelofibrózou a pravou polycytemií na českých hematologických pracovištích
| Title in English | Experience with ruxolitinib in the treatment of myelofibrosis and polycythaemia vera at Czech haematological institutions |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Article in Periodical |
| Magazine / Source | Transfuze a hematologie dnes |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | Drug toxicity; Myelofibrosis; Polycythaemia vera; Ruxolitinib; Treatment outcome |
| Description | Ruxolitinib, a Janus kinase 1 and 2 inhibitor, demonstrated efficacy in patients with myelofibrosis and polycythaemia vera in the randomized COMFORT-I, COMFORT-II and RESPONSE studies. Ruxolitinib demonstrated superior durable reduction of splenomegaly and disease-associated symptoms, maintenance of haematocrit values, improvement in quality of life and overall survival compared to placebo or best available therapy. Material and Methods: A retrospective analysis evaluated efficacy and tolerability of ruxolitinib in a cohort of unselected myelofibrosis and polycythaemia vera patients treated in routine clinical practice at 14 Czech haematological centres from 2013 to 2016. Results: Myelofibrosis -a total of 62 patients with myelofibrosis treated with ruxolitinib were evaluated. The most frequent indication for treatment was concurrent splenomegaly and constitutional symptoms in 54 (87.1%) cases. ReductionASTERISK OPERATOR1/3 in palpable spleen length was achieved in 43 (72.9%) patients with baseline splenomegaly at a median of 4 weeks after starting therapy. Constitutional symptoms receded in 38 (92.7%) of 41 patients at a median of 4 weeks after starting therapy. While on ruxolitinib, eleven (18.0%) patients developed grade 3-4 anaemia and thirteen (21.3%) patients developed grade 3-4 thrombocytopenia. Forty six (74.2%) patients survived. Twenty five (40.3%) patients discontinued therapy, most frequently due to inefficacy (16.1% of patients) or haematological toxicity (8.1% of patients). Median duration of ruxolitinib therapy was 41 weeks. Polycythaemia vera -a total of 8 patients with polycythaemia vera treated with ruxolitinib because of resistance or intolerance of previous treatment was analysed. Six (75.0%) patients achieved complete remission. All patients experienced resolution of disease-associated symptoms. No patient developed grade 3 to 4 toxicity. At evaluation, all patients remained on ruxolitinib with a median duration of 32.5 weeks. |
| Related projects: |